Howard Sofen

Health Science Clinical Professor

Olive View-UCLA Medical Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Howard Sofen is a Health Science Clinical Professor at Olive View-UCLA Medical Center in the United States. His research focuses on dermatological treatments, particularly in the areas of psoriasis, urticaria, and prurigo nodularis, as evidenced by his recent publications on various clinical trials. His work contributes to understanding the efficacy and safety of novel therapeutics in managing skin conditions.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Collaborators (3)

Akimichi Morita

JAPAN

View details

Amit G. Pandya

UNITED STATES

View details

Bruce Strober

Clinical Professor

Yale University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Howard Sofen

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials

Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis

Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial

Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials

Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

Safety and Efficacy of Ruxolitinib Cream for the Treatment of Vitiligo: A Randomised Controlled Trial Secondary Analysis at 3 Years

Collaborators (3)

Akimichi Morita

Amit G. Pandya

Bruce Strober

Make your next move.